If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

Share Price is delayed by 15 minutes
Get Live Data
2,060.00    -188.00 (-8.36%)
Bid:
2,074.00
Ask:
2,084.00
Spread: 10.00 (0.482%)
Market Cap: £1.37b
GNS Live PriceLast checked at - London Stock Exchange

Intraday Genus Share Chart

Director/PDMR Shareholding

20 Sep 2011 15:07

RNS Number : 5938O
Genus PLC
20 September 2011
 

20 September 2011

 

Genus plc

 

('Genus' or 'the Company')

 

Director/PDMR Shareholding

 

 

Genus announces that of 117,359 ordinary shares of 10 pence each in the Company ("Ordinary Shares") which vested today in favour of Richard Wood, Chief Executive, under the Genus 2004 Performance Share Plan (the "Plan"), 117,359 Ordinary Shares were today sold on behalf of Richard Wood at a price of 1,000 pence per Ordinary Share.

 

Richard Wood's direct shareholding in the Company stands at 45,856 Ordinary Shares which represents 0.08% of the issued share capital of the Company which is currently 60,239,150 Ordinary Shares.

 

Genus also announces that of 46,927 Ordinary Shares that vested today in favour of Ian Biggs, Head of Global Product & Business Strategy, under the Plan, 46,927 Ordinary Shares were today sold on behalf of Ian Biggs at a price of 1,000 pence per Ordinary Share.

 

Ian Biggs' direct shareholding in the Company stands at 3,375 Ordinary Shares which represents 0.01% of the issued share capital of the Company. In addition, he remains the beneficial owner of 78,415 conditional nil-cost options under the Plan.

 

Of 41,061 Ordinary Shares that vested today in favour of Thomas Philip Acton, Chief Operating Officer of Europe & The Far East, under the Plan, 31,061 Ordinary Shares were today sold on behalf of Thomas Philip Acton at a price of 1,000 pence per Ordinary Share.

 

Thomas Philip Acton's direct shareholding in the Company now stands at 31,104 Ordinary Shares which represents 0.06% of the issued share capital of the Company. In addition, he remains the beneficial owner of 78,415 conditional nil-cost options under the Plan.

 

Of 28,156 Ordinary Shares that vested today in favour of Ian Farrelly, Group Company Secretary & General Counsel, under the Plan, 28,156 Ordinary Shares were today sold on behalf of Ian Farrelly at a price of 1,000 pence per Ordinary Share.

 

Ian Farrelly has no direct shareholding in the Company. He remains the beneficial owner of 61,462 conditional nil-cost options under the Plan.

 

Genus further announces that of 1,619 Ordinary Shares which vested today in favour of Bill Christianson, Chief Operating Officer, The Americas, under the Genus 2004 Executive Share Option Plan (the "ESOP"), 1,619 Ordinary Shares were today sold on behalf of Bill Christianson at a price of 1,000 pence per Ordinary Share.

 

Bill Christianson has no direct shareholding in the Company and is the beneficial owner of 56,953 conditional nil-cost options and 18,970 market value share options.

 

Of 6,673 Ordinary Shares which vested today in favour of David Crosby, Group Financial Controller, under the ESOP, 6,673 Ordinary Shares were today sold on behalf of David Crosby at a price of 1,000 pence per Ordinary Share.

 

David Crosby has no direct shareholding in the Company and is the beneficial owner of 53,843 conditional nil-cost options.

 

 

For further information please contact:

 

Cara Crichton

Assistant Company Secretary

Genus plc

 

Tel: 01256 345996

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSURRSRANAKUAR
Date   Source Headline
31st Jul 20122:00 pmRNSBlocklisting Interim Review
31st Jul 20122:00 pmRNSTotal Voting Rights
31st Jul 20127:00 amRNSJoint Venture in China
4th Jul 20127:00 amRNSPre-Close Trading Statement
15th May 20124:09 pmRNSHolding(s) in Company
15th May 20124:08 pmRNSHolding(s) in Company
3rd May 20127:00 amRNSInterim Management Statement and Strategy Update
30th Apr 20122:00 pmRNSTotal Voting Rights
30th Mar 20122:00 pmRNSTotal Voting Rights
14th Mar 20122:00 pmRNSDirector/PDMR Shareholding
29th Feb 20122:00 pmRNSTotal Voting Rights
27th Feb 20124:25 pmRNSHolding(s) in Company
21st Feb 20123:16 pmRNSHolding(s) in Company
21st Feb 20122:30 pmRNSDirector/PDMR Shareholding
21st Feb 20127:00 amRNSInterim Results
31st Jan 20122:00 pmRNSBlocklisting Interim Review
31st Jan 201210:44 amRNSNotice of Results
16th Jan 20123:49 pmRNSHolding(s) in Company
4th Jan 20127:00 amRNSSenior Management Changes
30th Dec 201112:00 pmRNSTotal Voting Rights
30th Nov 20112:00 pmRNSTotal Voting Rights
10th Nov 201112:51 pmRNSResult of AGM
10th Nov 20117:00 amRNSAGM and Interim Management Statement
31st Oct 20112:00 pmRNSTotal Voting Rights
27th Oct 20112:00 pmRNSAnnual Information Update
11th Oct 201111:39 amRNSAnnual Report and Annual General Meeting
30th Sep 20112:44 pmRNSTotal Voting Rights
22nd Sep 20112:33 pmRNSHolding(s) in Company
20th Sep 20113:08 pmRNSAdditional Listing
20th Sep 20113:07 pmRNSDirector/PDMR Shareholding
9th Sep 201111:00 amRNSDirector/PDMR Shareholding
6th Sep 20117:00 amRNSPreliminary Results
31st Aug 20112:00 pmRNSTotal Voting Rights
29th Jul 20112:00 pmRNSBlocklisting Interim Review
29th Jul 20112:00 pmRNSTotal Voting Rights
4th Jul 20117:00 amRNSPre-close Trading Statement
25th May 20117:00 amRNSCEO Retirement and Appointment of Successor
12th May 20112:08 pmRNSHolding(s) in Company
11th May 20117:00 amRNSInterim Management Statement
28th Apr 20112:00 pmRNSTotal Voting Rights
31st Mar 20112:00 pmRNSTotal Voting Rights
10th Mar 20115:56 pmRNSHolding(s) in Company
9th Mar 201111:00 amRNSDirector Shareholding
28th Feb 20112:37 pmRNSTotal Voting Rights
22nd Feb 20117:00 amRNSInterim Results
31st Jan 20112:00 pmRNSBlocklisting Interim Review
31st Jan 20112:00 pmRNSTotal Voting Rights
27th Jan 20113:57 pmRNSNotice of Results
21st Jan 20113:36 pmRNSHolding(s) in Company
30th Nov 20102:00 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.